Compare WVVIP & YDESW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVVIP | YDESW |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 15 |
| Industry | Beverages (Production/Distribution) | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | 1996 | 2024 |
| Metric | WVVIP | YDESW |
|---|---|---|
| Price | $2.80 | $0.50 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.1K | ★ 30.8K |
| Earning Date | N/A | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 6.98 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,197,122.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.40 | $0.19 |
| 52 Week High | $15.05 | $2.11 |
| Indicator | WVVIP | YDESW |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 47.02 |
| Support Level | $2.74 | $0.35 |
| Resistance Level | $2.95 | $0.58 |
| Average True Range (ATR) | 0.20 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 18.18 | 26.72 |
Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.